First Time Loading...

Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422

Watchlist Manager
Sichuan Kelun Pharmaceutical Co Ltd Logo
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
Watchlist
Price: 33.67 CNY -0.12% Market Closed
Updated: May 17, 2024
Section:
 

Relative Value

The Relative Value of one Sichuan Kelun Pharmaceutical Co Ltd stock under the Base Case scenario is 34.46 CNY. Compared to the current market price of 33.67 CNY, Sichuan Kelun Pharmaceutical Co Ltd is Undervalued by 2%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
34.46 CNY
Undervaluation 2%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.3
P/S
P/S
Price to Sales
2.3
vs History
6
vs Industry
50
Median 3Y
1.8
Median 5Y
1.8
Industry
2.5
Forward
2.1
More Details
18.8
P/E
P/E
Price to Earnings
18.8
vs History
80
vs Industry
27
Median 3Y
20.2
Median 5Y
22.3
Industry
23.5
Forward
18
More Details
9.8
P/OCF
P/OCF
Price to OCF
9.8
vs History
58
vs Industry
36
Median 3Y
8.9
Median 5Y
11
Industry
17.4
More Details
71.2
P/FCFE
P/FCFE
Price to FCFE
71.2
vs History
11
vs Industry
9
Median 3Y
19.2
Median 5Y
19.2
Industry
24.3
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
19
vs Industry
32
Median 3Y
2.2
Median 5Y
2.2
Industry
2.1
More Details
2.3
EV/S
EV/S
Enterprise Value to Sales
2.3
vs History
20
vs Industry
48
Median 3Y
2
Median 5Y
2.1
Industry
2.6
Forward
2.1
More Details
4.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.4
vs History
14
vs Industry
47
Median 3Y
3.8
Median 5Y
3.9
Industry
5.3
More Details
12.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.8
vs History
87
vs Industry
29
Median 3Y
15.9
Median 5Y
18.5
Industry
13.7
Forward
11.9
More Details
12.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.8
vs History
87
vs Industry
34
Median 3Y
15.9
Median 5Y
18.5
Industry
17.4
Forward
15.6
More Details
9.8
EV/OCF
EV/OCF
Enterprise Value to OCF
9.8
vs History
73
vs Industry
38
Median 3Y
10.1
Median 5Y
13.1
Industry
16.2
More Details
16.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.1
vs History
65
vs Industry
24
Median 3Y
16
Median 5Y
20.9
Industry
18.6
More Details
1.8
EV/IC
EV/IC
Enterprise Value to IC
1.8
vs History
1
vs Industry
41
Median 3Y
1.4
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Sichuan Kelun Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
50.3B CNY 2.3 18.8 12.8 12.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
732.8B USD 20.4 119.4 58.5 66.5
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 16.5 45.1 33.6 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.2B USD 4.3 9.7 11.9 15.5
US
Merck & Co Inc
NYSE:MRK
331.4B USD 5.4 143.8 35.8 58.4
UK
AstraZeneca PLC
LSE:AZN
187.7B GBP 5 37.6 174.5 278.3
CH
Roche Holding AG
SIX:ROG
188.9B CHF 3.2 16.4 9.3 11
CH
Novartis AG
SIX:NOVN
182.4B CHF 3.4 11.5 8.7 12.8
US
Pfizer Inc
NYSE:PFE
161.5B USD 2.9 -522 12.9 20.6
P/E Multiple
Earnings Growth
CN
Sichuan Kelun Pharmaceutical Co Ltd
SZSE:002422
Average P/E: 50.3
18.8
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.4
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.7
-20%
US
Merck & Co Inc
NYSE:MRK
143.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.6
168%
CH
Roche Holding AG
SIX:ROG
16.4
26%
CH
Novartis AG
SIX:NOVN
11.5
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -522
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.